James C. Clemmer

President and Chief Executive Officer (CEO) at ANGIODYNAMICS

Board

Since April 1, 2016

Age

60 years

Education

Earned a Bachelor's degree from the Massachusetts College of Liberal Arts.

Tenure

Joined AngioDynamics as President and CEO in April 2016 and has led the company since then.

Also at ANGIODYNAMICS

CTC

Chad T. Campbell

Senior Vice President and General Manager, Oncology and Interventional Devices

Laura Piccinini

Senior Vice President and General Manager for Cardiovascular and International

LTW

Lawrence T. Weiss

Senior Vice President, Chief Legal Officer, and Corporate Secretary

About

James C. Clemmer, aged 60, is currently the President and Chief Executive Officer at AngioDynamics. He earned a Bachelor's degree from the Massachusetts College of Liberal Arts, which laid the foundation for his successful career in the medical supplies and technology industry.

He joined AngioDynamics in April 2016, assuming the roles of President and CEO at a pivotal point in his career.

Prior to his tenure at AngioDynamics, he held key leadership roles including serving as President of Covidien's $1.8 billion medical supplies segment and as Group President at Kendall Healthcare, where he developed strategic plans across multiple divisions.

In addition to his executive functions, Clemmer has contributed to the industry by serving on boards, including his role at Lantheus Medical Imaging, and demonstrated academic leadership as interim president at the Massachusetts College of Liberal Arts.

$ANGO Performance Under James C. Clemmer

Past Roles

Organization	Role	Date Range	Details
Massachusetts College of Liberal Arts	Interim President	Aug 2015 - Mar 1, 2016	Served as interim president at the institution
Covidien plc	President, Medical Supplies segment	Sep 2006 - Jan 2015	Directed strategic and day-to-day operations for a $1.8B global medical supplies segment
Kendall Healthcare	Group President	Jul 2004 - Sep 2006	Managed the U.S. business across five divisions and built the strategic plan before Covidien
Sage Products, Inc.	Early Career Role	N/A	Specific responsibilities or tenure not provided

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$783,000	Annual	3.0% increase from FY 2023 base salary of $760,000
Car Allowance	$18,692	Monthly (total annual)	$1,500 per month (less applicable taxes)
401(k) Match	$22,062	Annual	Matching contribution for FY 2024
Restricted Stock Units (RSUs)	92,181 units ($822,255 grant date fair value)	Vest over 4 years (25% per anniversary)	Granted on July 19, 2023; not tied to performance metrics; closing price on May 31, 2024 was $6.31
Stock Options	190,778 options ($820,002 grant date fair value)	Vest over 4 years; 10-year term	Exercise price of $8.92 per share; granted on July 19, 2023; no performance metrics attached

Performance Compensation

Data from FY 2024

Annual Cash Incentives

Metric	Target	Achievement	Bonus Payout (%)
Net Sales	$281.7 million	$270.7 million (59% of target bonus)	30%
Adjusted EBITDA	- $5.0 million	- $3.2 million (150% of target bonus)	45%
Corporate Objective (APEX Enrollment)	N/A	Achieved (125% of target bonus)	25%

Overall Target Incentive: 100% of base salary with a maximum payout potential of up to 200% if targets are exceeded
Total Payout: $783,000

Performance Share Awards

Detail	Value
Target Shares	184,361 shares
Maximum Shares	442,466 shares
Grant Date	July 19, 2023
Grant Date Fair Value	$1,756,960
Grant Date Stock Price	$8.92 per share
Vesting Schedule	Ratably over 4 years
Performance Metrics	Cumulative revenue and relative TSR vs. a comparator group
Performance Period	Three years (June 1, 2023 – May 31, 2026)

Note: Stock Options were granted with vesting based on continued employment and do not include specific performance metrics, and are therefore included in fixed compensation.